AWM Investment Company Inc. purchased a new position in Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 475,400 shares of the company's stock, valued at approximately $1,978,000. AWM Investment Company Inc. owned approximately 0.38% of Aquestive Therapeutics as of its most recent filing with the Securities and Exchange Commission.
A number of other large investors also recently added to or reduced their stakes in AQST. Legal & General Group Plc acquired a new position in shares of Aquestive Therapeutics during the second quarter valued at approximately $44,000. The Manufacturers Life Insurance Company acquired a new position in Aquestive Therapeutics in the 2nd quarter valued at $122,000. Elevation Point Wealth Partners LLC purchased a new position in Aquestive Therapeutics in the 2nd quarter valued at $42,000. Quantbot Technologies LP purchased a new position in Aquestive Therapeutics in the 2nd quarter valued at $99,000. Finally, Bratton Capital Management L.P. acquired a new stake in Aquestive Therapeutics during the 2nd quarter worth $40,813,585,000. 32.45% of the stock is currently owned by institutional investors and hedge funds.
Aquestive Therapeutics Stock Performance
Shares of AQST stock opened at $5.08 on Wednesday. The stock has a market capitalization of $637.59 million, a P/E ratio of -7.82 and a beta of 1.49. The company has a 50 day moving average price of $4.21 and a 200 day moving average price of $4.14. Aquestive Therapeutics, Inc. has a fifty-two week low of $2.93 and a fifty-two week high of $7.55.
Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last released its earnings results on Tuesday, August 11th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.10) by ($0.08). The company had revenue of $13.82 million during the quarter, compared to analysts' expectations of $11.42 million. On average, research analysts forecast that Aquestive Therapeutics, Inc. will post -0.5 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
A number of research analysts have weighed in on AQST shares. Wall Street Zen cut Aquestive Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, August 15th. HC Wainwright reaffirmed a "buy" rating and issued a $10.00 price target on shares of Aquestive Therapeutics in a report on Monday. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Aquestive Therapeutics in a research report on Friday, July 17th. Two analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $8.80.
Get Our Latest Stock Report on AQST
Insider Activity
In other Aquestive Therapeutics news, Director Julie Krop sold 25,000 shares of the firm's stock in a transaction dated Tuesday, June 23rd. The stock was sold at an average price of $5.02, for a total transaction of $125,500.00. Following the transaction, the director owned 25,000 shares of the company's stock, valued at approximately $125,500. This trade represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 6.81% of the company's stock.
About Aquestive Therapeutics
(
Free Report)
Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.
The company's lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Aquestive Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aquestive Therapeutics wasn't on the list.
While Aquestive Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
